Type 5 Phosphodiesterase Inhibitors in Treatment of Patients with Hyperactive Bladder

Sivkov A.V., Romih V.V., Korshunova E.S., Korshunov M.N.

Objective: comparative assessment of type 5 phosphodiesterase inhibitors (Vardenafil) and M-cholinolytic (Solifenacin) efficiency in treatment of patients with hyperactive bladder. Materials and methods: 26 males (group 1) with urodynamically confirmed hyperactive bladder and erectile dysfunction complaints took 10 mg of vardenafil twice a day for 8 weeks. 26 males in control group took 5 mg of solifenacin a day for 8 weeks. Treatment efficiency was evaluated due to visual analog scale, I-PSS score, Homma scale, urinary diary and, in first group, urodynamic assessments. Results: After 8-week course of vardenafil average daily micturition frequency decrease from 11,5 ± 3.0 to 10,0 ± 2,6, mean urgency frequency decrease from 2,3 ± 1,1 to 1,3 ± 0,8 were observed. Mean I-PSS score decreased from 13,5 ± 1,7 to 10,8 ± 0,9, mean Homma scale score – from 9,4 ± 2,3 to 8,1 ± 3,5. Visual analog scale analysis showed improvement (from 31 ± 15 to 68 ±1 1 mm) in patients' condition. After 8-week course of solifenacin daily micturition frequency decreased meanly from 11,0 ± 3,4 to 8,8 ± 2,4, urgency frequency decreased from 2,9 ± 1,4 to 1,9 ± 0,.9, also urge urinary incontinence frequency decreased from 2,6 ± 1,2 to 1,7 ± 0,8. Mean bladder capacity increased from 154,3 ± 19,6 to 205,0 ± 31,7 ml. Mean I-PSS score decreased from 11,3 ± 1,6 to 8,5 ± 1,8, and Homma scale score from 10,9 ± 2,1 to 7,9 ± 3,9. Conclusion: Despite solifenacin has few more benefits in treatment of patients with hyperactive bladder than vardenafil, the use of type 5 phosphodiesterase inhibitors in such patients is pathogeneticaly reasonable. Vardenafil relieves hyperactive symptoms and improves QoL.

AttachmentSize
Download article457.39 KB